Clinical Trial Update: The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether soluble beta-1,3/1,6-glucan reduces oral mucositis in head and neck cancer patients compared with placebo; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis

Drugs mentioned

• Soluble Beta-1,3/1,6-Glucan (soluble beta-1,3/1,6-glucan)

Snippet

Sponsor: Biotec Pharmacon ASA | Conditions: Oral Mucositis | Phase 2 | Status: COMPLETED